Quadrant Chemical Recalls Subpotent DermaZinc Spray Zinc Pyrithione Product
Quadrant Chemical Corporation is recalling DermaZinc Spray because the product is subpotent and does not meet the labeled 0.25% zinc pyrithione level.
What this means for you
Cosmetic or documentation issue. No expected health impact, but the manufacturer is correcting the affected products.
Our severity reasoning: The recall is classified as FDA Class III, which by definition is unlikely to cause adverse health consequences, fitting the Low severity criteria for minor labeling or potency issues without reported harm.
Plain-English summary
Quadrant Chemical Corporation is recalling DermaZinc Spray, 0.25% zinc pyritione, topical OTC, 4 fl oz bottle. The product is distributed by Dermallogix Partners, Inc. in Scarborough, ME.
The firm is recalling the product because it is subpotent and does not meet the labeled 0.25% zinc pyrithione level. The recall involves 4,800 bottles of Lot 022110-01, which were distributed in Maine.
Consumers who have this product should stop using it and contact the recalling firm for instructions on how to return or dispose of the product.
The recalled product
- Product
- DermaZinc Spray, 0.25% zinc pyritione, topical OTC, 4 fl oz bottle Distributed By: Dermallogix Partners, Inc. Scarborough, ME 04070
- Manufacturer
- Quadrant Chemical Corporation
- Category
- Drug — Topical OTC
- Hazard
- Affected units
- 4,800
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- Lot 022110-01
Distribution
Distributed in 1 state:
Related recalls
Same hazard · subpotent drug
See all →- ModerateAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- HighAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- HighAccord Healthcare Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- HighAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02